Articles tagged with Leukemia
A new study by NYU Langone Health researchers reveals how leukemia cells enter the lungs, causing severe breathing problems. Steroid treatment has been shown to improve respiratory function in AML patients with leukemic lung infiltration.
A 57-year-old MDS patient presented with CD34+ micromegakaryocytes and giant platelets in peripheral blood, raising concerns for acute leukemia misdiagnosis. Follow-up studies showed persistent iron-deficiency anemia and easy fatigability, while laboratory results revealed pancytopenia.
Acute leukemias with EWSR1 or FUS gene rearrangements display heterogeneous clinical and pathological characteristics. Cytogenetic karyotyping and fluorescence in situ hybridization remain crucial tools for detecting chromosomal translocations, while advanced molecular diagnostic methods are recommended to improve accurate diagnosis.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Dr. Josep Maria Ribera receives the EHA Clinical Excellence Award for his distinguished career in Acute Lymphoblastic Leukaemia treatment and patient care improvements. He is also recognized for his academic mentorship, training numerous haematologists who now lead positions in the field.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.
A new study has found that cancers with shrunken genomes are more widespread than previously thought, often associated with highly unstable tumours. Researchers developed a method to distinguish between two leukaemias based on recurring chromosome patterns, offering important clinical insights for patient treatment decisions.
A comprehensive long-term study has demonstrated the efficacy of molecular blood tests in influencing leukemia course. The study found that early intervention based on molecular markers can have a significant impact on disease progression.
Researchers at WashU Medicine conducted a clinical trial showing that genetically engineered donor stem cells can prevent toxic side effects and improve treatment options for patients with AML and MDS. The study found that removing the CD33 protein from donor stem cells helped target cancer cells while leaving healthy cells untouched.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new study found that targeted maternal screening can prevent adult T-cell leukemia/lymphoma, a rare and aggressive cancer caused by human T-cell leukemia virus type 1. The research identified high disease rates among non-Hispanic Caribbean-born US residents, particularly in Florida and New York.
Researchers developed a novel disease classification system and AI-assisted decision support tool to improve CMML care. The International CMML Prognostic Scoring System (iCPSS) demonstrates superior prognostic discrimination, stratifying patients into five risk groups with different survival outcomes.
Researchers have identified a single genetic change that drives the development of myeloid leukaemia in children with Down Syndrome. The study reveals a common vulnerability and treatment target, suggesting potential repurposed treatments. The genetic change, related to the GATA1 gene, is present at all stages of the disease.
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
A new study by the Barcelona Supercomputing Center reveals that women's immune systems undergo more pronounced changes with age, leading to a greater susceptibility to autoimmune diseases. In contrast, men experience less extensive immune system changes, but are at higher risk for certain blood cancers.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Researchers created a CRISPR-based tool to pinpoint genes the cancer turns off, restoring a key cancer-fighting gene in leukemia. The study found that blocking KDM4 enzymes can regain expression of the tumor-suppressor gene ZBTB7A, reducing leukemia burden while leaving normal blood formation largely unaffected.
Researchers developed an interpretable machine learning algorithm, scOMM, to classify cell types consistently across different single-cell methods. The integration strategies and scOMM establish a robust approach for cell atlas generation in complex tissues, leading to the discovery of previously undetected rare cell types.
The Josep Carreras Leukaemia Research Institute is joining forces with the Chinese Institute of Hematology and Blood Diseases Hospital to advance blood cancer research. The partnership aims to develop joint translational research programmes and accelerate the development of curative therapies for patients with blood cancers.
Researchers found that NUTM1 rearranged leukemia is distinct from other forms, with decreased DNA methylation and increased lifespan of blood cells. Leukemias with BRD9-NUTM1 fusion are extremely sensitive to chemotherapy, leading to improved clinical outcomes.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
Researchers develop new approach to prevent chemotherapy-related leukemia by analyzing blood samples from four clinical trials, showing a 26-36% reduction in blood cell growth with mutated TP53 gene. They also discover that monoclonal antibodies can turn neutrophils into cancer killers and induce tumor eradication in preclinical models.
Researchers at Albert Einstein College of Medicine have developed a new strategy to engineer immune cells that prolong their effectiveness, addressing a major limitation of current treatments. The new method generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection.
A new clinical diagnostic test using optical genome mapping (OGM) has been shown to detect additional genetic variants in nearly 20% of individuals with acute leukemia. OGM offers a comprehensive view of the genome, refining diagnosis and risk stratification, and improving therapy selection. The test's high diagnostic yield and ability...
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Researchers developed a biomimetic platform to enhance CAR T cell therapy against leukemia by creating a molecular bridge that reinforces the interface between CAR T cells and leukemia cells. This platform, called FACE, uses ferritin to bind to CD71 on leukemia cells, improving cell recognition and elimination.
Researchers from Dresden University Medicine developed a new treatment approach for relapsed acute myeloid leukemia (AML), combining standard therapy with the BCL2 inhibitor venetoclax. The innovative combination therapy has shown promising efficacy, increasing remission rates to 75% and improving patients' chances of recovery.
A new test detects infection-causing pathogens days before standard blood cultures, offering a potential approach to protecting vulnerable patients. The test, named plasma microbial cell-free DNA sequencing (mcfDNA-Seq), reliably identifies the most common bacteria and fungi that cause bloodstream infections in children with cancer.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
A new study has mapped the structure and function of healthy children's bone marrow cells, revealing age-dependent differences in blood cell formation. The atlas provides a valuable resource for researchers to better understand childhood leukemia and other blood disorders.
A multi-institutional effort aims to refine relapse prediction by identifying genetic markers in blood samples from patients with rare blood cancer. Analyzing blood samples from 190 patients, researchers found that tiny traces of persistent NPM1 mutation were linked to worse outcomes and lower survival rates.
Dr. Zon's pioneering research has illuminated how blood develops in embryos, leading to a deeper understanding of rare blood diseases, including pregnancy complications. His discoveries have also led to breakthrough treatments for genetic blood disorders affecting babies and children.
Researchers developed a new method to discover molecular glues through large-scale chemistry and cell-based screening. They identified compounds that selectively degrade ENL in leukemia cells, demonstrating the potential of this approach for targeting previously undruggable proteins.
The American Society of Hematology released guidelines for frontline and relapsed/refractory management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), outlining optimal approaches to treating high-risk patient populations. The guidelines highlight the need for additional research on immunotherapies and tr...
A case report investigates a woman's development of acute lymphoblastic leukemia and lymphoblastic lymphoma after receiving her second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, highlighting potential genetic and molecular mechanisms involved in disease pathogenesis.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
New studies from Sylvester reveal that 40% of cancers are preventable and that lifestyle interventions can play a crucial role in cancer treatment. Researchers also discovered PFAS on firefighter gear, which may limit exposure to hazardous chemicals linked to cancer.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
A new qualitative study highlights the profound toll of caregiving on family members of individuals with acute leukemia. Caregivers described living in two worlds, one dominated by cancer and another defined by their personal lives. The findings underscore the need for caregiver support as standard cancer care.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
Chromatin accessibility maps reveal that MDS stem cells gradually lose their normal identity and acquire characteristics typical of myeloid progenitors. A 'progenitor score' developed by the team tracks cell movement toward a progenitor-like state, correlating with disease severity and prognosis.
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
A new trial shows pirtobrutinib to be more effective than bendamustine plus rituximab in treating previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug demonstrated improved survival rates, a favorable safety profile, and lower adverse event rates compared to the standard treatment.
A new treatment using genome-edited immune cells has shown promising results in helping children and adults fight a rare form of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL). The gene therapy, known as BE-CAR7, uses base-editing to modify T-cells and destroy cancerous cells.
A Mount Sinai study found that the timing of a genetic mutation in children with leukemia can significantly impact its aggressiveness. The researchers discovered that leukemia caused by mutations occurring before birth is often more aggressive and harder to treat than those occurring later in life.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
A new study found that a chemo-free combination treatment outperformed targeted therapy and chemotherapy in patients with Ph+ acute lymphoblastic leukemia, achieving higher rates of event-free survival and complete remission. Researchers recommend this approach as the new standard of care for this patient group.
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met its primary endpoint in terms of overall response rate compared to covalent BTK inhibitor ibrutinib. The study suggests pirtobrutinib shows promise as initial BTK inhibitor therapy for patients with CLL and SLL.
Patients with B-acute lymphoblastic leukemia who have no evidence of remaining cancer cells experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation. The study's findings could allow more patients to avoid TBI and its associated long-term side effects.